Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors.

MLA

Nishimura, Tadashi, et al. “Impact of Immune‐related Adverse Events on Survival Outcomes in Extensive‐stage Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.” Cancer Medicine, vol. 13, no. 8, Apr. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1002/cam4.7188.

APA

Nishimura, T., Fujimoto, H., Fujiwara, T., Ito, K., Fujiwara, A., Yuda, H., Itani, H., Naito, M., Kodama, S., Furuhashi, K., Yagi, A., Saiki, H., Yasuma, T., Okano, T., Tomaru, A., Tanigawa, M., Yoshida, M., Hataji, O., Ibata, H., & D’Alessandro, G. C. N. (2024). Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer Medicine, 13(8), 1–10. https://doi.org/10.1002/cam4.7188

Chicago

Nishimura, Tadashi, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, et al. 2024. “Impact of Immune‐related Adverse Events on Survival Outcomes in Extensive‐stage Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.” Cancer Medicine 13 (8): 1–10. doi:10.1002/cam4.7188.